Who is recruiting patients for rare disease trials
Rare disease development is dominated by small and mid-sized biotechs: a company often runs one or two pivotal programs in a single ultra-rare indication, has no in-house patient-finding infrastructure, and depends on a handful of expert centers and patient organizations for every enrolled participant. That makes the sponsor, not the site, the natural buyer of recruitment, pre-screening, genetic testing partnerships and patient-advocacy outreach services.
Where the data comes from
Applicable clinical trials of FDA-regulated drugs and devices must be registered on ClinicalTrials.gov under FDAAA 801, and many European and Asian sponsors register there in addition to the EU Clinical Trials Information System (CTIS) or national registries. Each record carries a lead sponsor name, a sponsor class (Industry, NIH, Other, Network), the overall recruitment status, the conditions studied, the phase and the participating locations. The study record, not a press release, is the authoritative signal that enrollment is open.
As an illustration of scale: on 16 November 2026, a ClinicalTrials.gov query for studies with an Industry lead sponsor, status Recruiting, and the words rare, orphan, inborn errors or gene therapy anywhere in the record returned 463 studies from 282 distinct lead sponsors. Keyword matching misses many orphan indications that are never labelled “rare” in the record (for example hemophilia, Duchenne muscular dystrophy or specific lysosomal storage disorders), which is why the full population of sponsors is materially larger and is best estimated by matching conditions against the Orphanet nomenclature or FDA orphan designations.
Why sponsor-level grouping matters
The registry is organized per study. The same company can appear under a parent name, a local subsidiary or a US affiliate, so sponsor names have to be resolved to one company before trials can be counted. For business development, what matters is the company: how many rare disease studies it is enrolling at once, in which countries, and at which phase. A sponsor with a Phase 3 study in an ultra-rare disease and sites in a dozen countries has a very different recruitment problem from a Phase 1 gene therapy program enrolling a few children at one center.
| Phase | Typical rare disease enrollment | Recruitment pain point |
|---|---|---|
| Phase 1 / 1-2 | Single digits to a few dozen | Finding genetically confirmed patients who meet narrow age and severity criteria |
| Phase 2 | Tens of patients | Activating enough expert sites; natural-history comparators |
| Phase 3 | Dozens to low hundreds | Multi-country feasibility, travel support, competition with other sponsors for the same patients |
| Phase 4 / registries | Varies | Long-term follow-up and retention of treated patients |
Signals that a sponsor needs recruitment help
- Multiple recruiting studies in the same indication — the sponsor is competing with itself for a tiny patient pool.
- Start dates well in the past while status remains Recruiting — enrollment is slower than planned.
- Few listed locations — site footprint is thin and there may be room for additional sites or decentralized options.
- Pediatric gene therapy programs — eligibility often requires newborn screening or genetic testing partnerships to identify patients early.
- Orphan indications with an active patient organization — advocacy partnerships can shorten the path to eligible families.
How to read a study record
The ClinicalTrials.gov record shows the overall status (Not yet recruiting, Recruiting, Enrolling by invitation, Active not recruiting, Completed), and status changes are submitted by the sponsor, so a record can lag reality by weeks. Check the “Last update posted” date and the per-location recruitment status before outreach, and cross-reference the EU CTIS entry for European trials, which publishes country-level authorization dates.
A recruiting rare disease study is a time-boxed opportunity: once enrollment closes, the sponsor’s budget for patient-finding moves to the next program.